CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE 
OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES 
ANNEX 
1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE 
OF MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES 
The Member States should ensure that all conditions or restrictions with regard to the safe and 
effective use of the medicinal product described below are implemented. 
The Member States shall ensure that the MAH provides all physicians who are expected to prescribe 
or use Tamiflu a Direct Healthcare Professional Communication (DHPC) letter, the text of which is 
appended to the CHMP assessment report. The Member States shall agree with the MAH the 
communication plan for the DHPC letter. 
2 
 
 
 
